 | | | | President Joe Biden on Friday said he would nominate Robert Califf for a second stint as commissioner of the U.S. Food and Drug Administration, and urged the Senate to swiftly confirm him. | | | | | | The U.S. Federal Trade Commission said it approved certain modifications to Bristol Meyers Squibb's divestiture agreement that the FTC earlier approved and incorporated into its order as part of a consent required when the drugmaker acquired Celgene Corp in 2019. | | | | | | Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history. | | | | | | U.S. President Joe Biden's vaccine requirements are prompting more Americans to get COVID-19 shots, White House press secretary Jen Psaki said on Friday. | | | | | | Healthcare conglomerate Johnson & Johnson is spinning off its consumer health division that sells Listerine and Baby Powder, to focus on the more-profitable pharmaceutical and medical device market. | | | | | | Canada's COVID-19 cases are creeping higher as cold weather approaches, health officials said on Friday, and more restrictive public health measures may be needed if cases continue to climb. | | | | | | Johnson & Johnson on Friday said it would split into two companies, hiving off its consumer health division that sells Band-Aids and Baby Powder from its pharmaceuticals and medical devices business. | | | | | | Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history. | | | | | | The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. | | | | | | World Health Organization (WHO) officials said on Friday they were hoping to convene a meeting soon to set guidelines on the use of COVID-19 antiviral pills, saying they offered "very attractive" new prospects for clinical care. | | | | | |
